Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01637194 · ClinicalTrials.gov registry record · Phase 1
Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer
A Phase 1 study of Recurrent Colon Cancer and Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT01637194 is a Phase 1 study of Recurrent Colon Cancer and Recurrent Adenoid Cystic Carcinoma of the Oral Cavity that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 12 participants, below the 30-participant average among 10 other Recurrent Colon Cancer trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01637194, a Phase 1 study of Recurrent Colon Cancer and Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects and best dose of cetuximab when given together with everolimus in treating patients with metastatic or recurrent colon cancer or head and neck cancer. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of the tumor to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Everolimus may stop the growth of tumor cells by blocking blood flow to the tumor. Giving cetuximab together with everolimus may be an effective treatment for colon cancer or head and neck cancer
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL cetuximab
- OTHER pharmacological study
- DRUG everolimus
Study Locations (1)
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2008-11 |
| Est. Completion | 2011-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01637194
The ClinicalTrials.gov registry entry for NCT01637194 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 30-participant average among 10 other Recurrent Colon Cancer trials with a reported enrollment target (60% lower). The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Recurrent Colon Cancer appearing as the primary indexed condition, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT01637194 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01637194 about?
NCT01637194 is a clinical study titled "Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer". This phase I trial studies the side effects and best dose of cetuximab when given together with everolimus in treating patients with metastatic or recurrent colon cancer or head and neck cancer. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the abilit...
What is the current status of trial NCT01637194?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2008-11. Estimated completion is 2011-07.
What conditions does trial NCT01637194 study?
This clinical trial studies the following conditions: Recurrent Colon Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity.
What interventions are being tested in trial NCT01637194?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cetuximab (BIOLOGICAL), pharmacological study (OTHER), everolimus (DRUG).
Who is sponsoring clinical trial NCT01637194?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01637194 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Colon Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
COMPLETED · Phase 1
-
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer
COMPLETED · Phase 1
-
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
COMPLETED · Phase 1
-
Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery
COMPLETED · Phase 1
-
Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors
COMPLETED · Phase 1
-
CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
COMPLETED · Phase 1
Explore more on PlainTrial
Recurrent Colon Cancer
All registered trials for this condition
Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.